Post Reply
7921-7940 of 10899
87.5 should not be too tough to break....
You should have got in .845 on the opening bell !...
It's alredy cheonging !...
technically...i would like to see it break out at $0.875 for further upside
long term, think looonnnnnggg term..
Hello...JJ...maybe be having ....sharkfin later......
Cheong har........
Lian He Zhao Bao (Business) page 21
Cheer!!!!!!!!!!!!!!!!!!!BIG!!!!!!!!!!!!!!!!!!!!CHIONG!!!!!!!!!!!!!!!!!!!!!!!!!!!!AR!!!!!!!!!!!!!!!!!NO!!!!!!!!!!STOP!!!!!!!!!!
The article posted on Sunday Feb 17, 2008.
Bengster, in the newspaper BIG said he wants to have 20% market in Japan in 3 years time, whether it's exclusively for Terumo disctributor only, I don't know.
He admits that setting up this company made him "very poor", he pumped in USD 4.5 millions in 1990 to set up this company, spent about SGD 141millions for 7 years of R&D.
Now his next target is GET THE PROFIT, CREATE RESULTS, BUILD REPUTATION.
-the end- whether it will cheong later this morning, I don't know la.. but again, for long term, don't say 2 dollars, I think 3 dollars also no problem ~
Piss...JJ.... no target price...?
so it means Monday gonna shoot up? or ..hmmm..just curious
Is BIG planning to sell Biomatrix in Japan themself? I thought Terumo has exclusive Japan market. Could the exclusive Japan market refer to licensee only and therefore BIG (as the licensor) is not included? From my calculations, Terumo should get their Japan FDA approval in H2 of 2008. 3 years later, NOBORI should be selling in Japan for at least 2 years and it is definitely too conservative for Terumo to get only 20% Japan market share 3 years later. Terumo (being the largest Japanese medical device company) has very wide distribution channels in Japan and enjoy "very good relations" with home base Japanese doctors and hospitals. The Japs will tend to buy Japanese brand. Plus, NOBORI trials has the most impressive DES results this industry has ever seen. I think for Terumo, 3 years later they should be capturing close to 50% Japan market share with NOBORI.
From my understanding, BIG is currently selling their BMS S-stent in Japan market. However, from the extracts Lian He Zhao Bao that JackJames provided, the ex-CEO is only refering to BIG's own in-house Biomatrix sales. When was the article published?
OkieDokie, you are testing my mandarin dude..
well, let me give you the important dollar and figure.
(1) With this CE Mark, in Asia market (excluding Japan), there is a market value of SGD 1.2 Billion. Biosensor hopes to have 25% of market in 3 years time.
(2) BIG is planning to launch the new product on April 1 this year to Singapore, Indonesia, Malaysia, Thailand, Philliphine, Germany, Italy, Turkey, Switzerland, etc.
(3) Europe current market value is more than USD 1 billion, BIG plans to have 10% European market in 3 years time.
(4) Japan current market value is about USD 800 millions, BIG plans to have 20% of the market in 3 years time.
and some other details... anyway, this guy is confidence, never know he was brought up in Japan, study in the USA , and he was a mechanical engineering student~ impressive huh... how the hell he came to medical line?! read the newspaper la..
Ha Ha... This Patent No. 5,653,760 by Dr. Saffran expired on August 5, 2005, due to a failure to pay applicable maintenance fees.
http://www.patentfizz.com/fizzdisplay.php?patno=5653760
By MARK JEWELL
AP Business Writer
© 2008 The Associated Press
BOSTON ? Boston Scientific Corp. was ordered to pay nearly $432 million
in damages to a doctor who contends the medical device maker's
drug-coated heart stents violate his 1997 patent.
......
Dr.Saffran, a radiologist from Princeton, N.J., won a patent in 1997
involving a medicated fabric coating to help repair bone fractures. The
technology included a method to release medication within the body that
Saffran argued works in much the same way as stents' drug coatings.
"Dr.
Saffran is an independent inventor and his contributions to the
advancement of medical technology needed to be recognized and
rewarded," said Gary Hoffman, an attorney for Saffran with the firm
Dickstein Shapiro, which said Monday's award was among the largest jury
awards ever in a U.S. patent infringement case.
Saffran,
whose patent is valid until 2013, sued Boston Scientific in December
2005. Saffran did not request an injunction, so current sales of the
stents are unaffected by the verdict.
....
--------------------------------------------------------------------------------------------------------------------
Just wonder, whether BIG would be the next few DES companies to be sued as well? However, this patent only valid for a few more years, while BIG patents still have many years to go. What BIG need to do is to find one big fish and hit hard on it. Cheers!
Jackjames
Bring us to speed. What did the Lian He Zao Bao article says about BIG. Sorry for my china not powderful. My england too ! Thanks.
Judge Ups Damages in Stent Patent Case
Friday February 15, 7:57 pm ET
US Judge Increases Damages Against Boston Scientific in Stent Patent Case;
Award Totals $501M
BOSTON (AP) -- A patent judgment against Boston Scientific Corp. has jumped to $501 million after a judge tacked on an additional $69 million in interest.
U.S. District Judge John Ward ruled Thursday to expand the damages award -- decided by a federal jury in Marshall, Texas -- to cover interest on royalties dating to the medical device maker's 2004 U.S. launch of drug-coated heart stents.
Heart stents are tiny, mesh-wire tubes that prop open coronary arteries after they have been surgically cleared of fatty plaque.
After deliberating less than two hours, jurors awarded $432 million on Monday to Dr. Bruce Saffran, who argued the stents violated his 1997 patent covering technology to deliver medication within the body to heal injuries.
Natick, Mass.-based Boston Scientific recorded a $365 million charge against its fourth-quarter earnings to cover potential losses due to stent patent litigation. The company said on Tuesday that it didn't expect to record an additional charge for the new verdict, because it expected Ward or an appeals court would overturn the jury award.
Company spokesman Paul Donovan declined further comment Friday. Shares of Boston Scientific rose 24 cents, or 1.9 percent, to $12.81.
Boston Scientific and a unit of Johnson & Johnson dominate the market for newer model stents coated with drugs released to prevent post-surgical scar tissue from creating new blockages.
Saffran, a radiologist from Princeton, N.J., filed a similar patent challenge against Johnson & Johnson over its Cypher stent. That case is pending in Ward's court, an East Texas district that is a popular venue to bring patent claims.
Saffran's award involving Boston Scientific covers only past royalties. The judge also ordered that the question of future royalties be split into a separate case after the doctor files a new complaint covering that issue. Ward ordered Boston Scientific to file quarterly reports with the court on sales of its top-selling product, the Taxus Express stent, and the next-generation Taxus Liberte.
********************************************************************
Another important consideration for the big DES players to takeover BIG since BIG is holding many proprietary IPs and patents. The word PROPRIETARY is not just another fanciful word "for show" that i put in my posts. It is is a very important word. That is why i never missed them out when posting in forums. Some forumers may think why im so "wordy" in my posts. This "proprietary" thing cannot be excluded, esp BIG is in medical device industry where IP/patents are extremely important intangible assets. Hope you guys didn't missed out the "proprietary" word that i have posted all this while.
U.S. District Judge John Ward ruled Thursday to expand the damages award -- decided by a federal jury in Marshall, Texas -- to cover interest on royalties dating to the medical device maker's 2004 U.S. launch of drug-coated heart stents.
Heart stents are tiny, mesh-wire tubes that prop open coronary arteries after they have been surgically cleared of fatty plaque.
After deliberating less than two hours, jurors awarded $432 million on Monday to Dr. Bruce Saffran, who argued the stents violated his 1997 patent covering technology to deliver medication within the body to heal injuries.
Natick, Mass.-based Boston Scientific recorded a $365 million charge against its fourth-quarter earnings to cover potential losses due to stent patent litigation. The company said on Tuesday that it didn't expect to record an additional charge for the new verdict, because it expected Ward or an appeals court would overturn the jury award.
Company spokesman Paul Donovan declined further comment Friday. Shares of Boston Scientific rose 24 cents, or 1.9 percent, to $12.81.
Boston Scientific and a unit of Johnson & Johnson dominate the market for newer model stents coated with drugs released to prevent post-surgical scar tissue from creating new blockages.
Saffran, a radiologist from Princeton, N.J., filed a similar patent challenge against Johnson & Johnson over its Cypher stent. That case is pending in Ward's court, an East Texas district that is a popular venue to bring patent claims.
Saffran's award involving Boston Scientific covers only past royalties. The judge also ordered that the question of future royalties be split into a separate case after the doctor files a new complaint covering that issue. Ward ordered Boston Scientific to file quarterly reports with the court on sales of its top-selling product, the Taxus Express stent, and the next-generation Taxus Liberte.
********************************************************************
Another important consideration for the big DES players to takeover BIG since BIG is holding many proprietary IPs and patents. The word PROPRIETARY is not just another fanciful word "for show" that i put in my posts. It is is a very important word. That is why i never missed them out when posting in forums. Some forumers may think why im so "wordy" in my posts. This "proprietary" thing cannot be excluded, esp BIG is in medical device industry where IP/patents are extremely important intangible assets. Hope you guys didn't missed out the "proprietary" word that i have posted all this while.
see how this fellow goes on Monday......
YOU are the biggest fool if Biosensor is not one of your stock portfolion in year 2008 and for long term, it is brilliant of course.
Please buy one copy of Lian He Zhao Bao newspaper, it has one full page interview with Biosensor chairman, cut it and frame the newspaper with your stock purchase transaction slip. You will be proud anytime soon.
Cheers.... long live biosensor. (shit that CPF cannot support this counter )
$431m damages ! Wow ! More potential EI for Bios,citing the example below when Abbott's Xience & Boston's Promus are commercialised ! Dun play play !!! These two companies might as well spend the money wisely by making a bid for BIG to overcome potential litigation issue!
BOSTON SCIENTIFIC Announces Court Decision
February 12, 2008 ? Natick, Mass. ? Boston Scientific Corporation (NYSE: BSX) today announced that a U.S. District Court jury in Marshall, Texas has reached a verdict in a patent infringement suit brought against the Company by Dr. Bruce Saffran. The jury found that the Company's TAXUS® Express® and TAXUS® Liberte? drug-eluting stent products infringe Dr. Saffran's patent and that the patent is valid. No injunction was requested, but the jury awarded damages of $431 million.
The Company believes the jury verdict is unsupported by both the evidence and the law. On these grounds, the Company plans to seek to overturn the verdict in post-trial motions before the District Court and, if unsuccessful, to appeal to the U.S. Court of Appeals for the Federal Circuit. The Company believes it will prevail on appeal.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/ (You will be visiting a site outside EuroPCRonline, we are not responsible for its contents).
This is one darling stock which made many people happy...
So BIG starts to earn royalty from the 1st Nobori DES deployed in Europe. It is now a reality !!!
TERUMO Announces First CE Certified Nobori? DES in Use
February 15, 2008 ? Tokyo, Japan, Leuven, Belgium, Rome, Italy ? Terumo Corporation, announced today that the first CE certified Nobori? Drug-Eluting Coronary Stent System was successfully implanted in Europe. The Nobori? stent system is a truly new generation drug eluting stent (DES) with a bioresorbable polymer, offering best in class clinical results, excellent deliverability and strong patient safety profile. The company intends to expand the product from spring time 2008 widely to more than 20 countries in Europe, Asia, New Zealand and Africa.
The procedure was performed by Dr. Antonio Colombo, director of the Cardiac Catheterization Laboratory at Columbus Hospital and San Raffaele Hospital, Milan Italy in a live case transmission during JIM congress held in Rome.
"I successfully finished this highly tortuous right coronary case using Nobori? Drug-Eluting Coronary Stent System. It looks very promising. I look forward to seeing this new generation stent in daily use." said Dr. Antonio Colombo.
On January 16th 2008 Nobori?, as a first drug eluting stent employing bioresorbable polymer and drug Biolimus A9?, received CE Certificate. The launch of Nobori? stent will incorporate comprehensive clinical program to characterize the stent?s long-term safety and efficacy in a variety of patient populations. The program will enrol more than 5,000 patients in randomized trials and post-marketing registry.
The excellent efficacy and safety of the Nobori? stent have been confirmed through the several clinical trials included NOBORI 1 with its two phases, NOBORI CORE and NOBORI Pharmacokinetics study. In randomized studies versus Taxus Express® and Taxus Liberté® the Nobori? stent proved its non-inferiority and even superiority in efficacy endpoints such as late loss, with an exceptionally low frequency of adverse cardiac events and no stent thrombosis up to 1 year in phase 1 and 9 months in phase 2. In NOBORI CORE, a comparative study versus Cypher® stent other well known DES, Nobori? also showed excellent performance with very low rate of adverse cardiac events. The overall restenosis rate in all NOBORI trials was as low as 0.5% and no late stent thrombosis was recorded in any of the trials.